免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 中文乱伦字幕 | 久久骚| 美女美裸体爆射白浆久7久 亚洲最新av网站 | 久久久人妻 | 精品人妻一区二区三区含羞草 | 丁香五香天堂网 | 日韩久久精品 | 九色 蝌蚪 熟女 | 精品人妻一区二区三区浪潮在线 | 免费无码AV| 欧美专区第一页 | 日韩人妻精品 | 人妻丝袜中文字幕红桃影视 | 国产精品欧美一区二区三区苍井空 | JAVA无码免费专区A片 | 你懂的视频国产 | 高潮流白浆潮喷av | 极品少妇高潮啪啪AV无码 | TS慰菊前列腺在线观看 | 午夜成人无码在线免费观看视频 | 一区av | 久久精品99久久久久久久久 | 成人亚洲A片V一区二区三区蜜月 | 亚洲AV不卡在线观看 | 欧美成人影院亚洲成人图 | 精品人妻无码一区二区三区牛牛 | 免费国偷自产拍精品视频 | 久久久久久无码午夜精品直播 | 在线无码AV | 182午夜福利 | 亚洲AV无码成人精品区欧洲 | 亚洲男人网 | 人妻HDHDHD69XXXXХ男男 | 国产成人片在线观看 | 成人无码网站 | 天美传奇MV观看免费完整 | 日本三级日本三级日本三级极 | 国产 高潮 白浆 免费 | 国内大量偷窥精品视频 | 无码AV在线免费观看 | 狠狠干AV|